Pages that link to "Q36690500"
Jump to navigation
Jump to search
The following pages link to Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 (Q36690500):
Displaying 50 items.
- Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines (Q24531479) (← links)
- Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients (Q24538755) (← links)
- Pathogenesis of human immunodeficiency virus infection (Q24634681) (← links)
- Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design (Q24679395) (← links)
- Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 (Q28646835) (← links)
- Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding (Q28728517) (← links)
- Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 (Q29619512) (← links)
- A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. (Q31143293) (← links)
- Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection (Q33504604) (← links)
- Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites (Q33614461) (← links)
- Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes (Q33783763) (← links)
- An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. (Q33784679) (← links)
- Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model (Q33784708) (← links)
- Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys (Q33785114) (← links)
- Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques (Q33850605) (← links)
- A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression (Q33980469) (← links)
- Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission (Q34121239) (← links)
- Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 (Q34292765) (← links)
- Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage (Q34338411) (← links)
- Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial (Q34374835) (← links)
- Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies (Q34397758) (← links)
- Specificity of the autologous neutralizing antibody response (Q34415389) (← links)
- Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate (Q34551010) (← links)
- Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. (Q34983331) (← links)
- Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity (Q35101464) (← links)
- Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection (Q35635163) (← links)
- Identifying epitopes of HIV-1 that induce protective antibodies (Q35708836) (← links)
- Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera (Q35828529) (← links)
- The highly conserved aspartic acid residue between hypervariable regions 1 and 2 of human immunodeficiency virus type 1 gp120 is important for early stages of virus replication (Q35830393) (← links)
- Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. (Q35837553) (← links)
- Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype. (Q35838430) (← links)
- Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid) (Q35838613) (← links)
- Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding (Q35845976) (← links)
- Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. (Q35848078) (← links)
- Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies (Q35848446) (← links)
- Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. (Q35857331) (← links)
- Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. (Q35857683) (← links)
- N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120 (Q35870879) (← links)
- Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites (Q35873306) (← links)
- Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody. (Q35890076) (← links)
- Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer (Q36365085) (← links)
- Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. (Q36366296) (← links)
- The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection (Q36483346) (← links)
- Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. (Q36549220) (← links)
- Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein (Q36549382) (← links)
- Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains (Q36620087) (← links)
- Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies (Q36620408) (← links)
- Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. (Q36626986) (← links)
- Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization (Q36633911) (← links)
- In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. (Q36635367) (← links)